Activating Transcription Factor 3 And Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$767,794.00
Summary
We have shown that the transcription factor ATF3 suppresses bladder cancer spread. Turning off ATF3 is associated with disease progression in bladder and colorectal cancer. We will test whether levels of ATF3 can be used as a prognostic maker for disease progression, investigate the mechanisms underlying the actions of ATF3 in bladder and colorectal cancer and test whether therapeutically activating ATF3 can inhibit cancer progression.
Targeting FLT3 Kinase Activity To Treat Haematopoietic Neoplasms
Funder
National Health and Medical Research Council
Funding Amount
$673,045.00
Summary
Most leukaemias are incurable so it is important to find new treatments. For this to occur it is essential that the mutated genes that cause leukaemia are identified. We have generated a mouse with a mutation in a gene called c-Cbl that promotes the activation a protein called FLT3 that is involved in the development of many types of leukaemias. By treating mutant mice a drug that specifically suppresses the function of FLT3 we intend to identify the most effective treatments for human leukaemia ....Most leukaemias are incurable so it is important to find new treatments. For this to occur it is essential that the mutated genes that cause leukaemia are identified. We have generated a mouse with a mutation in a gene called c-Cbl that promotes the activation a protein called FLT3 that is involved in the development of many types of leukaemias. By treating mutant mice a drug that specifically suppresses the function of FLT3 we intend to identify the most effective treatments for human leukaemias associated with activated forms of FLT3.Read moreRead less
Molecular Characterisation Of Telomere Trimming And Its Role In Cell Proliferative Capacity
Funder
National Health and Medical Research Council
Funding Amount
$403,439.00
Summary
Telomeres are protective structures at the ends of chromosomes. Telomere length is a major determinant of how many times a cell can proliferate. We have recently discovered a rapid telomere shortening process that we have called telomere trimming. We will analyse the molecular details of this process to determine whether it could be used to shorten telomeres and stop cancer cell proliferation, and whether blocking it could increase cell proliferation in patients with short telomere syndromes.
Roles Of Cascades Of Transforming Growth Factor-beta And Matrix Metalloproteinases In The Impact Of Cancer Stem Cells On The Neoplasm Formation Of Oral Squamous Cell Carcinoma.
Funder
National Health and Medical Research Council
Funding Amount
$81,793.00
Summary
Failure of treatment of oral cancer patients is because the specific cancer cells escape from chemo-radiotherapy. These cells feature self-renew and fast growth, which are called cancer stem cells (CSC). We will test our hypothesis “the genes of TGF-?1 and MMP initiate CSCs” using our cell-mouse models to arrest cancer progression, and verify the impact of CSC on cancer formation. This study is critical to know how to arrest CSC and offer an opportunity to develop a targeted anti-cancer therapy.
Using MiR-200 To Find New Therapeutic Targets For Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$563,152.00
Summary
Neuroblastoma is one of the most common cancers in children. We have found that a genetic regulator, called microRNA, can limit the ability of neuroblastoma cells to invade surrounding tissues and metastasise. We aim use the microRNAs to find new therapeutic targets that may work in combination with existing treatments, reducing the short term toxicity and long term deleterious effects of current treatments.
Interaction Of TRF2 With DNA Repair Proteins In Alternative Lengthening Of Telomeres
Funder
National Health and Medical Research Council
Funding Amount
$297,246.00
Summary
10-15% of human cancers, including some of the most difficult-to-treat and aggressive, depend for their continuing growth on a molecular process called Alternative Lengthening of Telomeres (ALT). We have identified for the first time a protein whose normal role includes repressing ALT. We will study how this protein works, what its molecular partners are, and how these molecules interact with each other. This information is expected to lay the foundations for cancer treatments that target ALT.
Mechanistic And Functional Characterization Of The Atypical Kinase SgK269
Funder
National Health and Medical Research Council
Funding Amount
$271,879.00
Summary
The overall aim of this study is to characterize at a mechanistic and functional level the oncogenic role of SgK269. We will use quantitative proteomics and phosphoproteomics to characterize the signaling network role of SgK269 and subsequently undertake a detailed structure/function analysis of SgK269 in mammary epithelial cells. Our study will provide novel insights into the signaling mechanism and function of SgK269 and highlight the potential strategies for improved treatment of basal breast ....The overall aim of this study is to characterize at a mechanistic and functional level the oncogenic role of SgK269. We will use quantitative proteomics and phosphoproteomics to characterize the signaling network role of SgK269 and subsequently undertake a detailed structure/function analysis of SgK269 in mammary epithelial cells. Our study will provide novel insights into the signaling mechanism and function of SgK269 and highlight the potential strategies for improved treatment of basal breast cancers.Read moreRead less